Close

Heat Biologics (HTBX) Reports 1st Patient Dosed in New Cohort of Expanded Phase 2 Trial of HS-110 in Combination with Merck's (MRK) KEYTRUDA in NSCLC Trial

Go back to Heat Biologics (HTBX) Reports 1st Patient Dosed in New Cohort of Expanded Phase 2 Trial of HS-110 in Combination with Merck's (MRK) KEYTRUDA in NSCLC Trial

Heat Biologics (HTBX) Announces Clinical and Business Update

January 10, 2019 7:33 AM EST

Heat Biologics, Inc. (NASDAQ: HTBX) today provided a business update regarding the company's progress and plans for 2019.

Key highlights:

Phase 2 trial expanded to evaluate the benefit of HS-110 in combination with a different anti-PD-1 checkpoint inhibitor to treat patients earlier in the course of their metastatic diseaseSelected to deliver podium presentation of interim Phase 2 lung cancer data at ASCO-SITC Clinical Immuno-Oncology Symposium on February 28,... More